New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 3, 2014
10:29 EDTSPPIFDA approves Beleodaq for treatment of patients with PTCL
The FDA approved Beleodaq for the treatment of patients with peripheral T-cell lymphoma, PTCL, a rare and fast-growing type of non-Hodgkin lymphoma (NHL). The action was taken under the agency’s accelerated approval program. Beleodaq and Folotyn are marketed by Spectrum Pharmaceuticals (SPPI).
News For SPPI From The Last 14 Days
Check below for free stories on SPPI the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
07:07 EDTSPPISpectrum out-licenses rights for Greater China to CASI for three drugs
Subscribe for More Information
07:05 EDTSPPISpectrum out-licenses rights for Greater China to CASI for three drugs
Subscribe for More Information
September 16, 2014
07:02 EDTSPPISpectrum issued new patent for Beleodaq for injection
Spectrum Pharmaceuticals announced that the United States Patent and Trademark Office has issued U.S. Patent No. 8835501, which covers Beleodaq for Injection on September 16, 2014 with patent term adjustment from May 2026 to October 2027. In addition to the existing patent, covering the chemical entity of Beleodaq, this new patent covers the formulation of the product, strengthening and expanding significantly its industrial property protection.
September 9, 2014
07:01 EDTSPPISpectrum to advance SPI-2013 to Phase 3 trials
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use